Merck's $1.1 Billion Bet on RNAi.
- Published in:
- Bio-IT World, 2006, v. 5, n. 9, p. 10
- By:
- Publication type:
- Article
Works matching DE "ALNYLAM Pharmaceuticals Inc."
Results: 38
1
2
News Blast.
- Published in:
- Bio-IT World, 2006, v. 5, n. 2, p. 12
- Publication type:
- Article
3
News in brief.
- Published in:
- Nature Medicine, 2010, v. 16, n. 2, p. 144, doi. 10.1038/nm0210-144
- Publication type:
- Article
4
Silence is golden.
- Published in:
- Chemistry & Industry, 2010, n. 15, p. 14
- By:
- Publication type:
- Article
5
Designer RNA fights high bad cholesterol levels.
- Published in:
- Chemistry & Industry, 2008, n. 16, p. 8
- By:
- Publication type:
- Article
6
RNAi collaborations.
- Published in:
- Chemistry & Industry, 2007, n. 14, p. 7
- By:
- Publication type:
- Article
7
RNAi hype turns to hope.
- Published in:
- Chemistry & Industry, 2006, n. 10, p. 6
- By:
- Publication type:
- Article
8
Novartis, Alnylam team up again.
- Published in:
- Chemistry & Industry, 2006, n. 5, p. 5
- By:
- Publication type:
- Article
9
Novartis and Alnylam collaborate to develop new RNAi drug.
- Published in:
- Chemistry & Industry, 2005, n. 18, p. 8
- By:
- Publication type:
- Article
10
Merck first to enter RNAi collaboration.
- Published in:
- Chemistry & Industry, 2003, n. 18, p. 4
- Publication type:
- Article
11
Pharmaceutical company gets go-ahead for RNAi trial.
- Published in:
- Expert Review of Anticancer Therapy, 2009, v. 9, n. 3, p. 282
- Publication type:
- Article
12
Trial watch: Success in amyloidosis trials supports potential of systemic RNAi.
- Published in:
- Nature Reviews Drug Discovery, 2013, v. 12, n. 11, p. 818, doi. 10.1038/nrd4165
- By:
- Publication type:
- Article
13
Trial watch: Pioneering RNAi therapy shows antitumour activity in humans.
- Published in:
- Nature Reviews Drug Discovery, 2013, v. 12, n. 3, p. 178, doi. 10.1038/nrd3962
- By:
- Publication type:
- Article
14
News in brief.
- Published in:
- Nature Reviews Drug Discovery, 2009, v. 8, n. 8, p. 602, doi. 10.1038/nrd2965
- Publication type:
- Article
15
Alnylam casts IP into pool.
- Published in:
- Nature Biotechnology, 2009, v. 27, n. 9, p. 785, doi. 10.1038/nbt0909-785b
- By:
- Publication type:
- Article
16
Alnylam dealt blow.
- Published in:
- Nature Biotechnology, 2009, v. 27, n. 3, p. 213, doi. 10.1038/nbt0309-213b
- By:
- Publication type:
- Article
17
Companies jostle for lead in RNAi, despite uncertainties.
- Published in:
- Nature Biotechnology, 2007, v. 25, n. 11, p. 1191, doi. 10.1038/nbt1107-1191
- By:
- Publication type:
- Article
18
News in brief.
- Published in:
- Nature Biotechnology, 2007, v. 25, n. 10, p. 1070, doi. 10.1038/nbt1007-1070
- By:
- Publication type:
- Article
19
Profile: John Maraganore.
- Published in:
- 2007
- By:
- Publication type:
- Interview
20
News In Brief.
- Published in:
- Nature Biotechnology, 2006, v. 24, n. 8, p. 879, doi. 10.1038/nbt0806-879
- By:
- Publication type:
- Article
21
Private company profiles.
- Published in:
- Nature Biotechnology, 2003, v. 21, n. 7, p. BE23
- Publication type:
- Article
22
Tekmira Pharmaceuticals v. Alnylam Pharmaceuticals: A Classic Case of "Tekmira Said, Alnylam Said".
- Published in:
- Nanotechnology Law & Business, 2011, v. 8, n. 2, p. 92
- By:
- Publication type:
- Article
23
RNA therapy beckons as firms prepare for clinical trials.
- Published in:
- Nature, 2004, v. 429, n. 6994, p. 792, doi. 10.1038/429792b
- By:
- Publication type:
- Article
24
RNA silencing.
- Published in:
- Nature, 2009, v. 457, n. 7228, p. 395, doi. 10.1038/457395a
- By:
- Publication type:
- Article
25
Small RNAs: The Vehicle Laboratory.
- Published in:
- Nature, 2007, v. 450, n. 7172, p. 1117, doi. 10.1038/4501117b
- Publication type:
- Article
26
Silent running: the race to the clinic.
- Published in:
- Nature, 2006, v. 442, n. 7103, p. 614, doi. 10.1038/442614a
- Publication type:
- Article
27
In brief.
- Published in:
- Nature, 2005, v. 437, n. 7057, p. 317, doi. 10.1038/437317a
- Publication type:
- Article
28
Givosiran for the treatment of acute hepatic porphyria.
- Published in:
- Expert Review of Clinical Pharmacology, 2022, v. 15, n. 4, p. 383, doi. 10.1080/17512433.2022.2075848
- By:
- Publication type:
- Article
29
Gene delivery: Designer DNA give RNAi more spine.
- Published in:
- Nature Nanotechnology, 2012, v. 7, n. 6, p. 344, doi. 10.1038/nnano.2012.87
- By:
- Publication type:
- Article
30
Thrombosis: Balancing act.
- Published in:
- Nature, 2014, v. 515, n. s7528, p. S168, doi. 10.1038/515S168a
- By:
- Publication type:
- Article
31
RNA interference rebooted.
- Published in:
- Nature, 2014, v. 508, n. 7497, p. 443, doi. 10.1038/508443a
- By:
- Publication type:
- Article
32
Drug giants turn their backs on RNA interference.
- Published in:
- Nature, 2010, v. 468, n. 7323, p. 487, doi. 10.1038/468487a
- By:
- Publication type:
- Article
33
Alnylam, Dicerna tussle over RNAi tech.
- Published in:
- Nature Biotechnology, 2015, v. 33, n. 8, p. 791, doi. 10.1038/nbt0815-791a
- Publication type:
- Article
34
Alnylam's RNAi therapy targets amyloid disease.
- Published in:
- Nature Biotechnology, 2015, v. 33, n. 6, p. 577, doi. 10.1038/nbt0615-577a
- By:
- Publication type:
- Article
35
Startups on the menu: Alnylam.
- Published in:
- Nature Biotechnology, 2014, v. 32, n. 9, p. 866, doi. 10.1038/nbt.3009
- Publication type:
- Article
36
Markets, venture investors and big pharma interest in RNAi soars.
- Published in:
- Nature Biotechnology, 2014, v. 32, n. 3, p. 203, doi. 10.1038/nbt0314-203
- By:
- Publication type:
- Article
37
New patent broadly covering RNAi therapeutics.
- Published in:
- Journal of Intellectual Property Rights, 2010, v. 15, n. 2, p. 177
- Publication type:
- Article
38
Human microRNAs.
- Published in:
- Journal of Intellectual Property Rights, 2007, v. 12, n. 3, p. 374
- Publication type:
- Article